Multifocal Choroiditis Complications (CNV) Treatment: A Case Report

Nadon QAFA.
1Department of Ophthalmology, American Hospital of Tirana, Albania

Abstract: **Background:** Multifocal choroiditis is a condition characterized by intraocular inflammation and multifocal choroidal lesions occurring in the absence of any known ocular or systemic disease. Cystoid macular edema, subretinal fibrosis, and choroidal neovascularization are common causes of visual loss. **Description of the case:** A 22 years old female patient presented with a 3-month history of painless, progressive decreasing vision (RE > LE) and metamorphopsia in her both eyes. She was previously diagnosed and treated for multifocal choroiditis 6 months ago, in one other center. Complete eye examination, fluorescein angiography and OCT revealed the diagnosis of choroidal neovascular membrane (CNVM) as a result of Multifocal Choroiditis. The treatment was started in her both eyes with one combined intravitreal injection of Avastin (1.25mg/0.05ml) / Triamcinolon (4 mg/0.1ml), and 3 consecutive (every 4 weeks) intravitreal injections of Avastin (1.25 mg/0.05 ml). A close follow-up period of 11 months was completed. **Conclusion:** We reported a patient suffering from choroidal neovascular membrane as a result of multifocal choroiditis, with both eyes treated with one combined intravitreal injection of Avastin (1.25mg/0.05ml) / Triamcinolon (4 mg/0.1ml), and 3 consecutive (every 4 weeks) intravitreal injections of Avastin (1.25 mg/0.05 ml). The treatment resulted safe and effective in increasing the visual acuity (LE > RE) and improving the central retinal thickness. No vision threatening complication was noticed.

Keywords: Multifocal choroiditis, choroidal neovascular membrane, treatment

1. Introduction

Since the initial description of the disease by Nozik and Dorsch in 1973, hundreds of patients have been reported in the literature with multifocal choroiditis and panuveitis. The disease affects otherwise healthy young patients in their third decade (average age, 34 y; range, 6-74 y), with an incidence of bilateral involvement of 80%. A moderate racial and gender predisposition exists, with approximately 66% of patients being white and 80% of patients being female. Myopia is present in more than 85% of these individuals. Cystoid macular edema, subretinal fibrosis, and choroidal neovascularization are common causes of visual loss. The incidence of choroidal neovascular membrane formation varies from 25-40%.

2. Case Report

A 22 years old female patient presented with a 3-month history of painless, progressive decreasing vision (RE > LE) and metamorphopsia in her both eyes. She was previously diagnosed and treated for multifocal choroiditis 6 months ago with systemic steroids, in one other center (negative FTA-ABS, PPD, HLA-A29 negative and normal ACE levels and chest x-ray). Complete eye examination, FFA and OCT revealed the diagnosis of choroidal neovascular membrane (CNVM) as a result of Multifocal Choroiditis. Anterior chamber was quiet and mild vitreous reaction (cells) was noticed. Best corrected visual acuity (BCVA) was 20/200 and 6/20 in respectively her right and left eye (both eyes -3.0 sph. D). The central retinal thickness (CRT) was respectively 395 μm and 340 μm. The patient was treated with one combined intravitreal injection of Avastin (1.25mg/0.05ml) / Triamcinolon (4 mg/0.1ml), and 3 consecutive (every 4 weeks) intravitreal injections of Avastin (1.25 mg/0.05 ml). A close follow-up period of 11 months was completed. The BCVA was 60/200 and 18/20; CRT was reduced in 189 and 174μm respectively in the 5th month after treatment. In the last visit (month 11) the vision remained stable at 60/200 and 18/20 and the CRT was 236 and 195μm. No vision threatening complication was noticed.

3. Discussion

Management of choroidal neovascularization, a poor prognostic sign in multifocal choroiditis, can be difficult as the best treatment is yet to be determined. The current treatment options include periocular, intraocular, or oral corticosteroids; laser photocoagulation; photodynamic therapy; and, most recently, anti-VEGF therapy.

As multifocal choroiditis is supposed to be an inflammatory disease, we thought that the combination of one anti-inflammatory agent (triamcinolone) with one anti-VEGF (bevacizumab) drug would be the best treatment regimen for this case. This combination resulted in the functional and anatomical improvement which lasted for all the follow-up period.

4. Conflict of interest

The author declares that there is no conflict of interest.

References


**Picture 1**: Fluoresceine Angiography before treatment (both eyes).

**Picture 2**: Fundus photography on month 1 and 11 after treatment.
Picture 3: Right eye OCT images before treatment and during follow-up period.

Picture 4: Left eye OCT images before treatment and during follow-up period.